Hansoh Pharmaceutical Group Valuation
Is 3692 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 3692 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 3692 (HK$17.16) is trading below our estimate of fair value (HK$27.02)
Significantly Below Fair Value: 3692 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 3692?
Key metric: As 3692 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 3692's PE Ratio? | |
|---|---|
| PE Ratio | 20.1x |
| Earnings | CN¥4.71b |
| Market Cap | CN¥94.71b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 5.9x |
| Enterprise Value/EBITDA | 15.5x |
| PEG Ratio | 7.6x |
Price to Earnings Ratio vs Peers
How does 3692's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 14.6x | ||
1093 CSPC Pharmaceutical Group | 11x | 2.7% | HK$60.3b |
1177 Sino Biopharmaceutical | 26.7x | 12.9% | HK$59.5b |
3320 China Resources Pharmaceutical Group | 8.4x | 7.6% | HK$34.1b |
867 China Medical System Holdings | 12.4x | 21.4% | HK$18.6b |
3692 Hansoh Pharmaceutical Group | 20.1x | 2.7% | HK$101.8b |
Price-To-Earnings vs Peers: 3692 is expensive based on its Price-To-Earnings Ratio (20.1x) compared to the peer average (14.4x).
Price to Earnings Ratio vs Industry
How does 3692's PE Ratio compare vs other companies in the HK Pharmaceuticals Industry?
| 0 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|
| 0 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: 3692 is expensive based on its Price-To-Earnings Ratio (20.1x) compared to the Hong Kong Pharmaceuticals industry average (8.3x).
Price to Earnings Ratio vs Fair Ratio
What is 3692's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 20.1x |
| Fair PE Ratio | 12.8x |
Price-To-Earnings vs Fair Ratio: 3692 is expensive based on its Price-To-Earnings Ratio (20.1x) compared to the estimated Fair Price-To-Earnings Ratio (12.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | HK$17.16 | HK$23.17 +35.0% | 12.9% | HK$29.57 | HK$17.63 | n/a | 21 |
| Nov ’25 | HK$17.84 | HK$23.49 +31.7% | 12.9% | HK$29.99 | HK$17.88 | n/a | 21 |
| Oct ’25 | HK$20.95 | HK$23.35 +11.4% | 11.1% | HK$28.98 | HK$18.16 | n/a | 21 |
| Sep ’25 | HK$19.96 | HK$22.51 +12.8% | 12.3% | HK$28.63 | HK$18.03 | n/a | 21 |
| Aug ’25 | HK$16.50 | HK$20.07 +21.6% | 13.8% | HK$27.87 | HK$17.04 | n/a | 19 |
| Jul ’25 | HK$16.32 | HK$19.47 +19.3% | 15.2% | HK$27.77 | HK$14.91 | n/a | 18 |
| Jun ’25 | HK$16.06 | HK$19.22 +19.7% | 15.7% | HK$27.87 | HK$14.96 | n/a | 18 |
| May ’25 | HK$17.40 | HK$18.95 +8.9% | 15.8% | HK$27.95 | HK$14.79 | n/a | 19 |
| Apr ’25 | HK$15.48 | HK$18.10 +16.9% | 16.1% | HK$28.00 | HK$13.66 | n/a | 18 |
| Mar ’25 | HK$13.62 | HK$16.70 +22.6% | 20.8% | HK$25.17 | HK$11.17 | n/a | 19 |
| Feb ’25 | HK$11.86 | HK$16.82 +41.8% | 20.7% | HK$25.30 | HK$11.23 | n/a | 19 |
| Jan ’25 | HK$15.76 | HK$16.44 +4.3% | 21.8% | HK$25.52 | HK$11.33 | n/a | 19 |
| Dec ’24 | HK$15.88 | HK$16.32 +2.8% | 21.8% | HK$25.34 | HK$11.25 | n/a | 19 |
| Nov ’24 | HK$14.64 | HK$15.47 +5.7% | 23.5% | HK$24.74 | HK$10.07 | HK$17.84 | 19 |
| Oct ’24 | HK$10.66 | HK$15.63 +46.6% | 23.2% | HK$24.89 | HK$10.13 | HK$20.95 | 19 |
| Sep ’24 | HK$10.20 | HK$16.43 +61.1% | 23.3% | HK$27.72 | HK$10.18 | HK$19.96 | 19 |
| Aug ’24 | HK$12.32 | HK$17.48 +41.9% | 18.3% | HK$27.98 | HK$11.99 | HK$16.50 | 19 |
| Jul ’24 | HK$12.60 | HK$17.43 +38.3% | 17.0% | HK$26.48 | HK$12.39 | HK$16.32 | 19 |
| Jun ’24 | HK$13.10 | HK$17.76 +35.6% | 17.1% | HK$27.02 | HK$12.64 | HK$16.06 | 19 |
| May ’24 | HK$14.28 | HK$18.33 +28.3% | 17.3% | HK$27.79 | HK$13.00 | HK$17.40 | 18 |
| Apr ’24 | HK$13.64 | HK$18.29 +34.1% | 17.7% | HK$28.03 | HK$13.11 | HK$15.48 | 16 |
| Mar ’24 | HK$14.86 | HK$19.67 +32.4% | 19.1% | HK$30.99 | HK$13.90 | HK$13.62 | 15 |
| Feb ’24 | HK$16.30 | HK$20.28 +24.4% | 20.2% | HK$33.06 | HK$14.20 | HK$11.86 | 15 |
| Jan ’24 | HK$14.84 | HK$21.71 +46.3% | 38.7% | HK$47.84 | HK$13.96 | HK$15.76 | 14 |
| Dec ’23 | HK$14.84 | HK$21.21 +42.9% | 38.7% | HK$46.78 | HK$13.65 | HK$15.88 | 14 |
| Nov ’23 | HK$13.22 | HK$20.85 +57.7% | 39.0% | HK$46.23 | HK$13.49 | HK$14.64 | 14 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
China Shineway Pharmaceutical Group
HK$6.3b
An investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong.
2877
HK$8.29
7D
-5.1%
1Y
n/a
3SBio
HK$13.5b
An investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally.
1530
HK$5.85
7D
-0.2%
1Y
-18.3%
Innovent Biologics
HK$58.8b
A biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People’s Republic of China.
1801
HK$38.80
7D
4.4%
1Y
-8.6%